Menggang Yu
Mathematics · University of Michigan
Established · publishing since 1995Rising activity
Statistical Methods and InferenceProstate Cancer Treatment and ResearchAdvanced Causal Inference TechniquesStatistical Methods in Clinical TrialsStatistical Methods and Bayesian Inference
Publications
382
Citations
9,179
Est. group size
—
Recurring co-author estimate
Active years
32
Publishing since 1995
In context
Among 246 established Mathematics PIs within our index
Citations: 9,179p25 679 · p75 4,202 · cohort median 1,862
Publications / year (recent): 29.6p25 1.4 · p75 5.6 · cohort median 3
Typically publishes in teams of ~12 · 18% small-team papers (≤3 authors) · across 65 venues
Publication cadence
Publications per year over the last 10 years — averaging 29.6/year recently
Collaborators per year
Distinct co-authors at University of Michigan each year — a rough indication of whether the group around this researcher has been growing or contracting. An estimate from co-authorship, not a roster: collaborators are not necessarily lab members, and recent years can be under-counted while indexing catches up.
Recent publications
- Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial
Clinical Cancer Research · 2026
- A Quantitative Framework to Assess the Potential of Earlier Cancer Detection to Improve Cancer Survival
Cancer Epidemiology Biomarkers & Prevention · 2026
- Figure S6 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S15 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S8 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S14 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S16 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S12 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S9 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S3 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S5 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S7 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S2 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S17 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
- Figure S13 from High-Purity CTC RNA Sequencing Identifies Prostate Cancer Lineage Phenotypes Prognostic for Clinical Outcomes
2026
Publishes in
- Journal of Clinical Oncology×16
- Biometrics×12
- International Journal of Radiation Oncology*Biology*Physics×11
- arXiv (Cornell University)×11
- Cancer Research×9
Similar researchers
By research-topic overlap
- Donglin Zeng
Mathematics · University of Michigan
- Bingkai Wang
Mathematics · University of Michigan
- Colin B. Fogarty
Mathematics · University of Michigan
- Peisong Han
Mathematics · University of Michigan
- Weibin Mo
Mathematics · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile